Reported 3 days ago
Editas Medicine, a biotech company specializing in gene-editing treatments, has seen its stock plummet 97% since early 2021 due to challenges in developing effective therapies and increased competition. Although trading at $1.50 with a price target suggesting potential growth, the stock is considered too risky for long-term investors given its history of program cancellations and lack of human trials. The company is shifting focus to in vivo therapies and has reduced costs, but the uncertain timeline for any promising results makes it a gamble for investors.
Source: YAHOO